ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,269Medicare Part D Prescriptions Filled, Including Refills

Rank: 9 out of 41

$590K Total Retail Price of All Prescriptions

Rank: 8 out of 41

559 Patients Receiving at Least One Drug in Part D
94%Patients 65 Years and Older
58% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Minnesota
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 559 patients filled at least one prescription for a schedule two drug, compared to an average of 11%.

Schedule Three
Controlled Substances

2% of this provider’s 559 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

0% of this provider’s 9,756 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 20%.

Prescription Price

$57 was the average price of a prescription from this provider, compared to $52 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Minnesota
SERTRALINE HCL 567 521 1 17
LEVOTHYROXINE SODIUM 443 424 2 4
WARFARIN SODIUM 428 426 3 6
FUROSEMIDE 356 347 4 5
OMEPRAZOLE 327 308 5 2
DONEPEZIL HCL 323 317 6 13
NAMENDA 300 287 7 30
LISINOPRIL 291 271 8 1
QUETIAPINE FUMARATE 266 244 9 21
METOPROLOL TARTRATE 246 240 10 7
TRAZODONE HCL 229 218 11 14
POLYETHYLENE GLYCOL 3350 218 204 12 22
AMLODIPINE BESYLATE 188 180 13 9
ATENOLOL 181 179 14 10
LANTUS 174 168 15 25
POTASSIUM CHLORIDE 168 157 16 20
MIRTAZAPINE 164 150 17 15
GABAPENTIN 161 152 18 11
RISPERIDONE 154 154 19 31
TRAMADOL HCL 150 148 20 18
CARBIDOPA-LEVODOPA 147 147 21 36
CITALOPRAM HBR 146 145 22 8
DIVALPROEX SODIUM 141 128 23 35
NOVOLOG 111 111 24 42
PREDNISONE 105 103 25 27
IPRATROPIUM-ALBUTEROL 99 97 26 48
SEROQUEL 92 88 27 52
LIDODERM 90 87 28 47
LOSARTAN POTASSIUM 87 82 29 23
SPIRONOLACTONE 80 73 30 72
ALENDRONATE SODIUM 72 72 31 29
SIMVASTATIN 70 62 32 3
METOPROLOL SUCCINATE 67 67 33 16
METFORMIN HCL 67 67 33 19
CARVEDILOL 64 63 35 41
OLANZAPINE 64 64 35 28
ALLOPURINOL 60 59 37 43
GALANTAMINE HBR 57 57 38 147
IPRATROPIUM BROMIDE 56 54 39 149
ESCITALOPRAM OXALATE 55 55 40 80
BUDESONIDE 54 52 41 155
ATORVASTATIN CALCIUM 54 29 41 26
GLIPIZIDE 52 52 43 53
RANITIDINE HCL 51 50 44 40
DIGOXIN 51 50 44 38
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 5, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.